Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0VHDYJ
ADC Name
WO2022057651A1 ADC-19
Synonyms
WO2022057651A1 ADC 19
   Click to Show/Hide
Organization
Sichuan Kelun Pharmaceutical Co., Ltd.
Drug Status
Investigative
Indication
In total 4 Indication(s)
Bladder cancer [ICD11:2C94]
Investigative
Breast cancer [ICD11:2C60-2C65]
Investigative
Lung cancer [ICD11:2C25]
Investigative
Non-small cell lung cancer [ICD11:2C25]
Investigative
Drug-to-Antibody Ratio
7.75
Structure
Antibody Name
31HZ
  Antibody Info 
Antigen Name
Nectin-4 (NECTIN4)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
WO2022057651A1 ADC-19 linker
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 90.61
%
NCI-H322M cells
Minimally invasive lung adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 100
%
NCI-H322M cells
Minimally invasive lung adenocarcinoma
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
206.1
ng/mL
T-47D cells
Invasive breast carcinoma
Half Maximal Effective Concentration (EC50) 
1.28
ug/mL
T24 cells
Bladder carcinoma
Half Maximal Effective Concentration (EC50) 
1.39
ug/mL
A-549 cells
Lung adenocarcinoma
Half Maximal Effective Concentration (EC50) 
9.38
ug/mL
NCI-N87 cells
Gastric tubular adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 90.61% (Day 21) Positive NECTIN4 expression (NECTIN4 +++/++)
Method Description
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model NCI-H322M CDX model
In Vitro Model Minimally invasive lung adenocarcinoma NCI-H322M cells CVCL_1557
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 21) Positive NECTIN4 expression (NECTIN4 +++/++)
Method Description
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model NCI-H322M CDX model
In Vitro Model Minimally invasive lung adenocarcinoma NCI-H322M cells CVCL_1557
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 206.10 ng/mL Positive NECTIN4 expression (NECTIN4 +++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Invasive breast carcinoma T-47D cells CVCL_0553
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 1.28 ug/mL High NECTIN4 expression (NECTIN4 +++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Bladder carcinoma T24 cells CVCL_0554
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 1.39 ug/mL High NECTIN4 expression (NECTIN4 +++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Lung adenocarcinoma A-549 cells CVCL_0023
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 9.38 ug/mL Positive NECTIN4 expression (NECTIN4 +++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
References
Ref 1 Anti-nectin-4 antibody, conjugate including same, and application thereof; 2022-03-24.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.